Robert J Hariri bought $70k of CELU
Chief Executive Officer at Celularity Inc. 40,000 shares at an average of $1.74, traded Nov 28, 2022, filed Nov 28, 2022.
Score components
- +25RoleCEO
- +8Trade size$70k at market
- -5Relative to holdingsUnder 1% of holdings (0.5%)
- +8Price context87% below the 52-week high
- 0ClusterNo other insider buying within 14 days
- 0Repeat buyingFirst buy in 90 days
- 0Track recordToo few past buys to judge (0 with prices)
What happened after comparable buys
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0000899243-22-037102, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Nov 28, 2022 | POpen-market purchase Class A Common Stock | +40,000 | $1.74 | $70k | 8,024,996 | Nov 28, 2022 |
Related signals
Other insiders at Celularity Inc and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 50Moderate | CELUbuy Celularity Inc | Kok Thay Lim owner | $5.3M 21,410,983 shares | +71% | |
| 33Weak | CELUbuy Celularity Inc | Robert J Hariri Chief Executive Officer | $17k 10,000 shares | +0% | |
| 41Moderate | CELUbuy Celularity Inc | Robert J Hariri Chief Executive Officer | $68k 40,000 shares | +0% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.